AADI BIOSCIENCE, INC. EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • November 10th, 2021 • Aadi Bioscience, Inc. • Pharmaceutical preparations • New Jersey
This Executive Employment Agreement (the “Agreement”) is entered into as of October 19, 2021 by and between Aadi Bioscience, Inc. (“Aadi”), and Loretta Itri, M.D. (“Executive”). This Agreement will be effective October 21, 2021 (the “Effective Date”). As you know, Aadi recently consummated a merger (with the parent company of the merger being formerly known as Aerpio Pharmaceuticals, Inc. (“Aerpio”)) and Aerpio changed its name to Aadi Bioscience, Inc. as part of the merger. Aadi, together with any other subsidiaries, including the entity employing you, shall be referred to in this letter as the “Company”.
ContractLicense Agreement • November 10th, 2021 • Aadi Bioscience, Inc. • Pharmaceutical preparations • New York
Certain identified information marked with [***] has been excluded from this exhibit because it is not material and is of the type that the registrant treats as private and confidential.
FIRST AMENDMENT TO OFFICE LEASEOffice Lease • November 10th, 2021 • Aadi Bioscience, Inc. • Pharmaceutical preparations
This FIRST AMENDMENT TO OFFICE LEASE (“First Amendment”) is made and entered into as of August 30, 2021, by and between BRE SUNSET COAST, LLC, a Delaware limited liability company (“Landlord”), and AADI BIOSCIENCE, INC., a Delaware corporation (“Tenant”).
AMENDMENT NO. 1 TO AMENDED AND RESTATED LICENSE AGREEMENTLicense Agreement • November 10th, 2021 • Aadi Bioscience, Inc. • Pharmaceutical preparations • New York
This AMENDMENT NO. 1 TO AMENDED AND RESTATED LICENSE AGREEMENT (the “First Amendment”) is effective this 30th day of August, 2021 (the “Amendment Effective Date”) by and between Abraxis Bioscience, LLC, a Delaware limited liability company (“Abraxis”), and AADi Bioscience, Inc., a Delaware corporation (“AADi”).
AMENDED AND RESTATED LICENSE AGREEMENTLicense Agreement • November 10th, 2021 • Aadi Bioscience, Inc. • Pharmaceutical preparations • New York
This AMENDED AND RESTATED LICENSE AGREEMENT (this “Restated Agreement”), is made as of November 15, 2019 (the “Restatement Effective Date”), by and between Abraxis BioScience, LLC, a Delaware limited liability company, a wholly owned subsidiary of Celgene Corporation (“Abraxis”), and AADi Bioscience, Inc., a Delaware corporation, formerly known as AADi LLC (“AADi”). Abraxis and AADi are sometimes herein each referred to as a “Party” and collectively the “Parties.” As of the Restatement Effective Date, this Restated Agreement amends and restates in its entirety that certain License Agreement between Abraxis and AADi, dated as of April 9, 2014 (the “Effective Date”), as amended by that certain First Amendment to the License Agreement between Abraxis and AADi, dated as of October 3, 2016 (such amendment, the “First Amendment” and such agreement together with the First Amendment, the “Original Agreement”).
